JPH06507172A - 転換可能なミクロエマルジョン処方剤 - Google Patents
転換可能なミクロエマルジョン処方剤Info
- Publication number
- JPH06507172A JPH06507172A JP4511743A JP51174392A JPH06507172A JP H06507172 A JPH06507172 A JP H06507172A JP 4511743 A JP4511743 A JP 4511743A JP 51174392 A JP51174392 A JP 51174392A JP H06507172 A JPH06507172 A JP H06507172A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- microemulsion
- water
- surfactant
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000004530 micro-emulsion Substances 0.000 title claims description 424
- 239000000203 mixture Substances 0.000 title claims description 384
- 238000009472 formulation Methods 0.000 title description 49
- 239000003921 oil Substances 0.000 claims description 341
- 239000004094 surface-active agent Substances 0.000 claims description 265
- 239000013543 active substance Substances 0.000 claims description 180
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 145
- 238000000034 method Methods 0.000 claims description 140
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 136
- 239000008346 aqueous phase Substances 0.000 claims description 133
- 229910001868 water Inorganic materials 0.000 claims description 115
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 114
- -1 erythroboetins Proteins 0.000 claims description 91
- 239000012071 phase Substances 0.000 claims description 84
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 81
- 239000000839 emulsion Substances 0.000 claims description 81
- 102000004169 proteins and genes Human genes 0.000 claims description 78
- 108090000623 proteins and genes Proteins 0.000 claims description 78
- 108060001064 Calcitonin Proteins 0.000 claims description 73
- 102000055006 Calcitonin Human genes 0.000 claims description 72
- 229960004015 calcitonin Drugs 0.000 claims description 72
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical group N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 72
- 239000000126 substance Substances 0.000 claims description 68
- 125000004432 carbon atom Chemical group C* 0.000 claims description 66
- 150000005690 diesters Chemical class 0.000 claims description 66
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 59
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 48
- 239000000194 fatty acid Substances 0.000 claims description 48
- 229930195729 fatty acid Natural products 0.000 claims description 48
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 48
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 47
- 239000007787 solid Substances 0.000 claims description 43
- 230000001225 therapeutic effect Effects 0.000 claims description 42
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 40
- 239000000600 sorbitol Substances 0.000 claims description 40
- 230000000694 effects Effects 0.000 claims description 37
- 238000005192 partition Methods 0.000 claims description 37
- 230000002163 immunogen Effects 0.000 claims description 36
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 33
- 239000003607 modifier Substances 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 28
- 239000000122 growth hormone Substances 0.000 claims description 27
- 150000005691 triesters Chemical class 0.000 claims description 27
- 102000004877 Insulin Human genes 0.000 claims description 25
- 108090001061 Insulin Proteins 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 108010063738 Interleukins Proteins 0.000 claims description 24
- 102000015696 Interleukins Human genes 0.000 claims description 24
- 229940125396 insulin Drugs 0.000 claims description 24
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 22
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 22
- 229940088623 biologically active substance Drugs 0.000 claims description 22
- 229940047120 colony stimulating factors Drugs 0.000 claims description 22
- 229940047122 interleukins Drugs 0.000 claims description 22
- 230000000975 bioactive effect Effects 0.000 claims description 21
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 20
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 20
- 229940122331 Fibrinogen antagonist Drugs 0.000 claims description 19
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 18
- 150000002148 esters Chemical class 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 150000004665 fatty acids Chemical class 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 17
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- 102100033367 Appetite-regulating hormone Human genes 0.000 claims description 16
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 16
- 235000011187 glycerol Nutrition 0.000 claims description 16
- 210000003491 skin Anatomy 0.000 claims description 16
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 15
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 14
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 239000003114 blood coagulation factor Substances 0.000 claims description 14
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 13
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 13
- 210000002615 epidermis Anatomy 0.000 claims description 13
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 12
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 12
- 239000002442 collagenase inhibitor Substances 0.000 claims description 12
- 230000012010 growth Effects 0.000 claims description 12
- 150000003626 triacylglycerols Chemical class 0.000 claims description 12
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 12
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 11
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims description 11
- 239000004380 Cholic acid Substances 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 150000001298 alcohols Chemical class 0.000 claims description 11
- 239000012736 aqueous medium Substances 0.000 claims description 11
- 235000019416 cholic acid Nutrition 0.000 claims description 11
- 229960002471 cholic acid Drugs 0.000 claims description 11
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 10
- 108010064733 Angiotensins Proteins 0.000 claims description 10
- 102000015427 Angiotensins Human genes 0.000 claims description 10
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 claims description 10
- 108010077895 Sarcosine Proteins 0.000 claims description 10
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 10
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 10
- 108010004977 Vasopressins Proteins 0.000 claims description 10
- 102000002852 Vasopressins Human genes 0.000 claims description 10
- 150000001336 alkenes Chemical class 0.000 claims description 10
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical class C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 10
- 239000004359 castor oil Substances 0.000 claims description 10
- 235000019438 castor oil Nutrition 0.000 claims description 10
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 claims description 10
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 10
- 239000003102 growth factor Substances 0.000 claims description 10
- 239000004310 lactic acid Substances 0.000 claims description 10
- 235000014655 lactic acid Nutrition 0.000 claims description 10
- 229940043230 sarcosine Drugs 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 235000002906 tartaric acid Nutrition 0.000 claims description 10
- 239000011975 tartaric acid Substances 0.000 claims description 10
- 229960003726 vasopressin Drugs 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 229930195725 Mannitol Natural products 0.000 claims description 9
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 9
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 9
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 9
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 9
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 9
- 239000011148 porous material Substances 0.000 claims description 9
- 150000003871 sulfonates Chemical class 0.000 claims description 9
- 102000018997 Growth Hormone Human genes 0.000 claims description 8
- 108010051696 Growth Hormone Proteins 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 8
- 239000007764 o/w emulsion Substances 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 7
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 7
- 238000009826 distribution Methods 0.000 claims description 7
- 230000002267 hypothalamic effect Effects 0.000 claims description 7
- 239000000787 lecithin Substances 0.000 claims description 7
- 229940067606 lecithin Drugs 0.000 claims description 7
- 235000010445 lecithin Nutrition 0.000 claims description 7
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 6
- 102000035195 Peptidases Human genes 0.000 claims description 6
- 108091005804 Peptidases Proteins 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 229940009976 deoxycholate Drugs 0.000 claims description 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 6
- 150000002772 monosaccharides Chemical class 0.000 claims description 6
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims description 5
- 229940115457 cetyldimethylethylammonium bromide Drugs 0.000 claims description 5
- 150000002016 disaccharides Chemical class 0.000 claims description 5
- VCAVAURZPNANDQ-UHFFFAOYSA-N ethyl-hexadecyl-dimethylazanium Chemical group CCCCCCCCCCCCCCCC[N+](C)(C)CC VCAVAURZPNANDQ-UHFFFAOYSA-N 0.000 claims description 5
- VUFOSBDICLTFMS-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)CC VUFOSBDICLTFMS-UHFFFAOYSA-M 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 5
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 4
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 4
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 4
- 239000000854 Human Growth Hormone Substances 0.000 claims description 4
- 239000005639 Lauric acid Substances 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 4
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 4
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims description 4
- 229960001661 ursodiol Drugs 0.000 claims description 4
- 206010072170 Skin wound Diseases 0.000 claims description 3
- 239000008177 pharmaceutical agent Substances 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 102000003951 Erythropoietin Human genes 0.000 claims 5
- 108090000394 Erythropoietin Proteins 0.000 claims 5
- 229940105423 erythropoietin Drugs 0.000 claims 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 5
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical class CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 claims 4
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 3
- 229910021653 sulphate ion Inorganic materials 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 108020001621 Natriuretic Peptide Proteins 0.000 claims 1
- 102000004571 Natriuretic peptide Human genes 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 229960003237 betaine Drugs 0.000 claims 1
- 239000012867 bioactive agent Substances 0.000 claims 1
- 210000002837 heart atrium Anatomy 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 claims 1
- 239000000692 natriuretic peptide Substances 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 150000003385 sodium Chemical class 0.000 claims 1
- ZEMPKEQAKRGZGQ-VBJOUPRGSA-N triricinolein Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC)COC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-VBJOUPRGSA-N 0.000 claims 1
- 150000003674 ursodeoxycholic acids Chemical class 0.000 claims 1
- 235000019198 oils Nutrition 0.000 description 188
- 235000018102 proteins Nutrition 0.000 description 64
- 239000003814 drug Substances 0.000 description 45
- 229940079593 drug Drugs 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 39
- 235000013772 propylene glycol Nutrition 0.000 description 34
- 239000011149 active material Substances 0.000 description 33
- 238000002844 melting Methods 0.000 description 32
- 230000008018 melting Effects 0.000 description 32
- 239000007788 liquid Substances 0.000 description 27
- 239000004615 ingredient Substances 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 24
- 241000700159 Rattus Species 0.000 description 22
- 239000011575 calcium Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 239000012530 fluid Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- 239000000829 suppository Substances 0.000 description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 16
- 210000001124 body fluid Anatomy 0.000 description 16
- 239000010839 body fluid Substances 0.000 description 16
- 229910052791 calcium Inorganic materials 0.000 description 16
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 16
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 15
- 201000006747 infectious mononucleosis Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000002671 adjuvant Substances 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000003240 coconut oil Substances 0.000 description 12
- 235000019864 coconut oil Nutrition 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 210000004400 mucous membrane Anatomy 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
- 229920000053 polysorbate 80 Polymers 0.000 description 9
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 8
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 229960002446 octanoic acid Drugs 0.000 description 8
- 239000008389 polyethoxylated castor oil Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000000576 coating method Methods 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000955 prescription drug Substances 0.000 description 7
- 239000012646 vaccine adjuvant Substances 0.000 description 7
- 229940124931 vaccine adjuvant Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000003739 neck Anatomy 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 235000019482 Palm oil Nutrition 0.000 description 5
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000004020 conductor Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 150000004667 medium chain fatty acids Chemical class 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000002540 palm oil Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000012266 salt solution Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 241000972773 Aulopiformes Species 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001746 atrial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 229960001438 immunostimulant agent Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 235000019515 salmon Nutrition 0.000 description 4
- 239000002195 soluble material Substances 0.000 description 4
- 150000003460 sulfonic acids Chemical class 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 239000004907 Macro-emulsion Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000019486 Sunflower oil Nutrition 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Chemical group 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- WCVOGSZTONGSQY-UHFFFAOYSA-N 2,4,6-trichloroanisole Chemical compound COC1=C(Cl)C=C(Cl)C=C1Cl WCVOGSZTONGSQY-UHFFFAOYSA-N 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 2
- 235000006008 Brassica napus var napus Nutrition 0.000 description 2
- 240000000385 Brassica napus var. napus Species 0.000 description 2
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 2
- RKZXQQPEDGMHBJ-LIGJGSPWSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentakis[[(z)-octadec-9-enoyl]oxy]hexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC RKZXQQPEDGMHBJ-LIGJGSPWSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 2
- 229960002682 cefoxitin Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 150000002190 fatty acyls Chemical group 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000033687 granuloma formation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002356 laser light scattering Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000114726 Acetes Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940123073 Angiotensin antagonist Drugs 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 241000357297 Atypichthys strigatus Species 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- YBTVCUSZMGXJNW-FDNBCEJMSA-N C1=C2OCOC2=CC(/C=C\2/C(=C/C=3C=C4OCOC4=CC=3)/COC/2=O)=C1 Chemical compound C1=C2OCOC2=CC(/C=C\2/C(=C/C=3C=C4OCOC4=CC=3)/COC/2=O)=C1 YBTVCUSZMGXJNW-FDNBCEJMSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000776471 DPANN group Species 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241001427367 Gardena Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027783 Moaning Diseases 0.000 description 1
- 241000357291 Monodactylus argenteus Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical class C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 241001460678 Napo <wasp> Species 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 150000001218 Thorium Chemical class 0.000 description 1
- 241001504592 Trachurus trachurus Species 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000981595 Zoysia japonica Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002369 angiotensin antagonist Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- DXZDEAJXVCLRLE-UHFFFAOYSA-N azepin-2-one Chemical compound O=C1C=CC=CC=N1 DXZDEAJXVCLRLE-UHFFFAOYSA-N 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000013216 cat model Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940009025 chenodeoxycholate Drugs 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 150000001954 decanoic acid esters Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940009979 dehydrocholate Drugs 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 239000010512 hydrogenated peanut oil Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XSEOYPMPHHCUBN-FGYWBSQSSA-N hydroxylated lecithin Chemical group CCCCCCCCCCCCCCCCCC(=O)OC(COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCC[C@@H](O)[C@H](O)CCCCCCCC XSEOYPMPHHCUBN-FGYWBSQSSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000010874 maintenance of protein location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- JOLPFRQHFARWCF-UHFFFAOYSA-N propane-1,2,3-triol;prop-1-ene Chemical compound CC=C.OCC(O)CO JOLPFRQHFARWCF-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940053191 simply saline Drugs 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- XBYKLNAHPCSCOD-UHFFFAOYSA-M sodium;2-hydroxy-5-methoxybenzoate Chemical compound [Na+].COC1=CC=C(O)C(C([O-])=O)=C1 XBYKLNAHPCSCOD-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 150000003680 valines Chemical class 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)ミクロエマルジョンの全容量に基づいて約60容量%迄の、有効量の 生物的に活性な治療用水溶性物質を含んでいる内部分散された水相、 (b)少なくとも1種の製薬上受け入れられる油を含んでいる連続油相、及び (c)約7〜14のHLB値を有している表面活性剤又は表面活性剤混合物、 を含み、 該活性物質がカルシトニン、インシュリン、フィブリノゲン拮抗剤、成長ホルモ ン放出ペプチド、インターロイキン類、エリトロボエチン類、コロニー刺激因子 類、RGDペプチド類、ヘマト調節ペプチド類(hematoregulato rypeptide)、バソブレッシン、コラーゲナーゼ阻害剤類、アンギオデ ンシン阻害剤類、哺乳類成長ホルモン類、エリトロボエチン類、ヘパリン類、イ ンターロイキン類、凝固因子類、コロニー刺激因子類、視床下部性放出ペプチド 類、組織プラスミノーゲン活性化因子、アトリアルナトリウム利尿性ペプチド類 (atrialnatriureticpeptide)、腫瘍壊死因子からな る群から選択される、油中水滴型ミクロエマルジョン。 2.油相が、約9〜83個の炭素原子を有するグリセロールのトリエステル及び 約7〜55個の炭素原子を有するブロピレングリコールのジエステルからなる群 から選択される油成分を含む請求項1に記載の組成物。 3.表面活性剤又は表面活性剤の混合物が、セチルジメチルエチルアンモニウム ブロマイド、セチルピリジニウムクロライド及び他の塩;C8−32脂肪酸及び その塩;コール酸及びその誘導体例えばデオキシコレート、及びその塩、ウルソ デオキシコール酸、及びタウロコール酸;酒石酸のC8−56ジエステル類;ホ スファチジル酸及びホスファチジルセリン等の燐脂質類;乳酸のC5−29モノ エステル類;アルキル、オレフィン及びアルキルアリール誘導体を含めたC8− 20スルホネート類;トリデシル及びドデシルベンゼンスルホン酸類;及びC5 −33サルコシン及びベタイン誘導体類;ホスファチジルエタノールアミン、ス フィゴミエリン類、エトキシル化ひまし油;C5−29モノグリセリド類及びそ のエトキシル化誘導体類;C15−60ジグリセリド類及び1〜90のPOE基 を有しているそのポリオキシエチレン誘導体類;長鎖脂肪酸のC10−40エス テル類;C10−40アルコール類;C8−96エトキシル化脂肪酸エステル類 ;C14−130庶糖脂肪酸エステル類及びC20−130ソルビトール及びソ ルビタンモノエステル、ジエステル及びトリエステル類及びその0〜90のPO E基を有しているポリオキシエチレン(POE)誘導体類からなる群から選ばれ る請求項2に記載の組成物。 4.ミクロエマルジョンが水相中に改質剤を含有し、その改質剤がソルビトール 、ポリエチレングリコール、ブロピレングリコール、マンニトール、及びモノ及 びジサッカライド類からなる群から選択され、そしてその改質剤が水性媒体の添 加によって油中水滴型のミクロエマルジョン、を水中油滴型ミクロエマルジョン に転換させるのに十分な量で存在する請求項3に記載の組成物。 5.油相が本質的に約7〜55個の炭素原子を有しているブロピレングリコール のジエステルからなる請求項3に記載の組成物。 6.表面活性剤又は表面活性剤混合物のHLBが約8〜13である請求項3に記 載の組成物。 7.表面活性剤又は表面活性剤混合物がC5−29モノグリセリド類、C15− 60ジグリセリド類、C8−96エトキシル化脂肪酸エステル類、C20−13 0ソルビトール及びソルビタンモノエステル、ジエステル及びトリエステル、及 び0〜90POE基を有しているそのポリオキシエチレン(POE)誘導体類か らなる群から選択される請求項6に記載の組成物。 8.油中水滴型ミクロエマルジョンの容量%が水相に対し約0.1〜約15であ り、油相に対して約50〜90であり、表面活性剤又は表面活性剤混合物に対し 約2〜50である請求項4又は7の組成物。 9.活性物質がフィブリノゲン拮抗剤である請求項3、4又は8に記載の組成物 。 10.活性物質がシクロ(S,S)−Nα−アセチル−Cys−(Nα−メチル )Arg−Gly−Asp−Pen−NH2の配列を有するペプチドである請求 項9に記載の組成物。 11.活性物質が成長ホルモン放出ペプチドである請求項3、4又は8に記載の 組成物。 12.活性剤が配列【配列があります】を有しているペプチドである請求項11 に記載の組成物。 13.活性剤がカルシトニン、インシュリン、及び人成長ホルモンからなる群か ら選択される請求項3、4、又は8に記載の組成物。 14.(a)ミクロエマルジョンの全容量に基づいて約60容量%迄の、生物活 性の治療用水溶性物質の有効量を含む内部的に分散された水相、 (b)約7〜55個の炭素原子を有しているブロピレングリコールのジエステル 及び約9〜83個の炭素原子を有しているグリセロールのトリエステルから本質 的になる連続油相、及び (c)約7〜14のHLB値を有している表面活性剤又は表面活性剤混合物、 を含む油中水滴型ミクロエマルジョン。 15.生物活性物質が蛋白質、ペプチド、免疫原又は製薬上活性の物質であり、 そして油相が約7〜55個の炭素原子を有するブロピレングリコールのジエステ ルからなる請求項14に記載の組成物。 16.活性物質が蛋白質又はペプチドであり、活性剤の水対油分配係数が10: 1よりも大きな請求項15に記載の組成物。 17.表面活性剤又は表面活性剤混合物がセチルジメチルエチルアンモニウムブ ロマイド、セチルピリジニウムクロライド及び他の塩;C8−32脂肪酸及びそ の塩;コール酸及びその誘導体例えばデオキシコレート、及びその塩、ウルソデ オキシコール酸、及びタウロコール酸;酒石酸のC8−56ジエステル類;ホス ファチジル酸及びホスファチジルセリン等の燐脂質類;乳酸のC5−29モノエ ステル類;アルキル、オレフィン及びアルキルアリール誘導体を含めたC8−2 0スルホネート類;トリデシル及びドデシルベンゼンスルホン酸類;及びC5− 33サルコシン及びべタイン誘導体類;ホスファチジルエタノールアミン、スフ ィゴミエリン類、エトキシル化ひまし油;C5−29モノグリセリド類及びその エトキシル化誘導体類;C15−60ジグリセリド類及び1〜90のPOE基を 有しているそのポリオキシエチレン誘導体類;長鎖脂肪酸のC10−40エステ ル類;C10−40アルコール類;C8−96エトキシル化脂肪酸エステル類; C14−130庶糖脂肪酸エステル類、及びC20−130ソルビトール及びソ ルビタンモノエステル、ジエステル及びトリエステル類及びその0〜90のPO E基を有しているそのポリオキシエチレン(POE)誘導体類からなる群から過 ばれる請求項16に記載の組成物。 18.表面活性剤又は表面活性剤混合物のHLBが約8〜13である請求項17 に記載の組成物。 19.ミクロエマルジョンが水相中に改質剤を含有し、その改質剤がソルビトー ル、ポリエチレングリコール、ブロピレングリコール、マンニトール、及びモノ 及びジサッカライド類からなる群から選択され、そして水性媒体の添加により油 中水滴型ミクロエマルジョンを水中油滴型ミクロエマルジョンに転換させるのに 十分な量で存在する請求項17に記載の組成物。 20.非水相が本質的にステロールを含まない請求項17に記載の組成物。 21.表面活性剤又は表面活性剤混合物が約5以下のHLB値を有する少なくと も1種の表面活性剤と、HLB値約9以上を有している少なくとも1種の表面活 性剤を含有している請求項17に記載の組成物。 22.油中水滴型のミクロエマルジョンの容量%が水相に対し約0.1〜約15 であり、油相に対し約50〜90であり、表面活性剤又は表面活性剤混合物に対 し約2〜50である請求項17又は19に記載の組成物。 23.粒径が約150nm以下である請求項22に記載の組成物。 24.表面活性剤又は表面活性剤混合物がC5−29モノグリセリド類、C15 −60ジグリセリド類、C8−96エトキシル化脂肪酸エステル類、C20−1 30ソルビトール及びソルビタンモノエステル、ジエステル及びトリエステル、 及び0〜90POE基を有しているそのポリオキシエチレン(POE)誘導、体 類からなる群から選ばれる請求項23に記載の組成物。 25.活性物質がフィブリノゲン拮抗剤である請求項17、19又は24に記載 の組成物。 26.活性物質がシクロ(S,S)−Nα−アセチル−Cys−(Nα−メチル )Arg−Gly−Asp−Pen−NH2の配列を有するペプチドである請求 項25に記載の組成物。 27.活性物質が成長ホルモン放出ペプチドである請求項17、19又は24に 記載の組成物。 28.活性物質が配列【配列があります】を有しているペプチドである請求項2 7に記載の組成物。 29.活性物質がカルシトニン、インシュリン、フィブリノゲン拮抗剤、成長ホ ルモン放出ペプチド、インターロイキン類、エリトロボエチン類、コロニー刺激 因子類、RGDペプチド類、ヘマト調節ペプチド類、バソブレッシン、コラーゲ ナーゼ阻害剤類、アンギオテンシン阻害剤類、哺乳類成長ホルモン類、エリトロ ボエチン類、ヘバリン類、インターロイキン類、凝固因子類、コロニー刺激因子 類、視床下部性放出ペプチド類、組織プラスミノーゲン活性化因子、アトリアル ナトリウム利尿性ペプチド類、腫瘍壊死因子からなる群から選択される請求項1 7、19、24に記載の組成物。 30.活性物質がカルシトニン類、インシュリン類、及び人成長、ホルモン類か らなる群から選択される請求項29に記載の組成物。 31.(a)ミクロエマルジョンの全容量に基づいて約60容量%迄の、生物活 性な治療用水溶性物質の有効量を含む内部的に分散された水相、 (b)少なくとも1種の製薬上受け入れられる油を含む連続油相、及び (c)約7〜14のHLB値を有している表面活性剤又は表面活性剤混合物、 を含む室温で固体である油中水滴型ミクロエマルジョン。 32.生物活性物質が蛋白質、ペプチド、免疫原又は製薬上活性物質である請求 項31に記載の組成物。 33.活性物質が蛋白質又はペプチドであり、活性物質の水対油分配係数が10 :1よりも大きな請求項31に記載の組成物。 34.油相が約9〜83個の炭素原子を有するグリセロールのトリエステル類、 及び約7〜55個の炭素原子を有するブロピレングリコールのジエステル類を含 む請求項33に記載の組成物。 35.表面活性剤又は表面活性剤の混合物がセチルジメチルエチルアンモニウム ブロマイド、セチルビリジニウムクロライド及び他の塩;C8−32脂肪酸及び その塩;コール酸及びその誘導体例えばデオキシコレート、及びその塩、ウルソ デオキシコール酸、及びタウロコール酸;酒石酸のC8−56ジエステル類;ホ スファチジル酸及びホスファチジルセリン等の燐脂質類;乳酸のC5−29モノ エステル類;アルキル、オレフィン及びアルキルアリール誘導体を含めたC8− 20スルホネート類;トリデシル及びドデシルベンゼンスルホン酸類;及びC5 −33サルコシン及びべタイン誘導体類;ホスファチジルエタノールアミン、ス フィゴミエリン類、エトキシル化ひまし油;C5−29モノグリセリド類及びそ のエトキシル化誘導体類;C15−60ジグリセリド類及び1〜90のPOE基 を有しているそのポリオキシエチレン誘導体類;長鎖脂肪酸のC10−40エス テル類;C10−40アルコール類;C8−96エトキシル化脂肪酸エステル類 ;C14−130庶糖脂肪酸エステル類及びC20−130ソルビトール及びソ ルビタンモノエステル、ジエステル及びトリエステル類及びその0〜90のPO E基を有しているポリオキシエチレン(POE)誘導体類からなる群から選ばれ る請求項34に記載の組成物。 36.表面活性剤又は表面活性剤混合物のHLBが約8〜13である請求項35 に記載の組成物。 37.表面活性剤又は表面活性剤混合物が、約5以下のHLB値を有している少 なくとも1種の表面活性剤と、約9以上のHLB値を有している少なくとも1種 の表面活性剤とを含有している請求項35に記載の組成物。 38.水相がミクロエマルジョンの約0.1〜約20容量%である請求項35に 記載の組成物。 39.油相がミクロエマルジョンの約50〜90容量であり、表面活性剤がミク ロエマルジョンの約2〜50容量%である請求項38に記載の組成物。 40.粒径が約150nm以下である請求項39に記載の組成物。 41.ミクロエマルジョンが水相中に改質剤を含有し、その改質剤がソルビトー ル、ポリエチレングリコール、ブロピレングリコール、マンニトール、及びモノ 及びジサッカライド類からなる群から選ばれ、そして水性媒体の添加により油中 水滴型ミクロエマルジョンを水中油滴型ミクロエマルジョンに転換させるのに十 分な量で存在する請求項35又は39に記載の組成物。 42.油が19〜23個の炭素原子を有しているブロピレングリコールのジエス テルであり、表面活性剤がカブリン酸及びカブリル酸のモノグリセリド及びジグ リセリドの混合物である請求項41に記載の組成物。 43.活性物質がカルシトニン、インシュリン、フィブリノゲン拮抗剤、成長ホ ルモン放出ペプチド、インターロイキン類、エリトロポエチン類、コロニー刺激 因子類、RGDペプチド類、ヘマト調節ペプチド類、バソブレッシン、コラーゲ ナーゼ阻害剤類、アンギオテンシン阻害剤類、哺乳類成長ホルモン類、エリトロ ポエチン類、ヘバリン類、インターロイキン類、凝固因子類、コロニー刺激因子 類、視床下部性放出ペプチド類、組織プラスミノーゲン活性化因子類、アトリア ルナトリウム利尿性ペプチド類、腫瘍壊死因子からなる群から選択される請求項 35、39又は41に記載の組成物。 44.活性物質がカルシトニン類、インシュリン類、及び人成長ホルモン類から なる群から選択される請求項43に記載の組成物。 45.活性物質がフィブリノゲン拮抗剤である請求項35、39又は41に記載 の組成物。 46.活性物質がシクロ(S,S)−Nα−アセチル−Cys−(Nα−メチル )Arg−Gly−Asp−Pen−NH2の配列を有するペプチドである請求 項45に記載の組成物。 47.活性物質が成長ホルモン放出ペプチドである請求項35、39又は41に 記載の組成物。 48.活性物質が配列【配列があります】を有しているペプチドである請求項4 7に記載の組成物。 49.(a)(1)ミクロエマルジョンの全容量に基づいて約60容量%迄の、 生物活性の治療用水溶性物質の有効量を含む内部的に分散された水相、 (2)少なくとも1種の製薬上受け入れられる油を含む連続油相、及び (3)約7〜14のHLB値を有している表面活性剤又は表面活性剤混合物を含 む油中水滴型ミクロエマルジョンを準備し、そして、 (b)有効量の油中水滴型ミクロエマルジョンを非経口的、経口的又は任意の他 の粘膜経由で投与することからなる動物に生物活性物質を投与する方法。 50.生物活性物質が蛋白質ペプチド、免疫原又は製薬上活性物質である請求項 49に記載の方法。 51.活性物質が蛋白質又はペプチドであり、活性物質の水対油分配係数が10 :1よりも大きく、粒径が150nm以下である請求項49に記載の方法。 52.油相が約7〜55個の炭素原子を有しているブロピレングリコールのジエ ステルと約9〜83個の炭素原子を有しているグリセロールのトリエステルから なる群から選択される油を含んでいる請求項51に記載の方法。 53.表面活性剤又は表面活性剤の混合物がセチルジメチルエチルアンモニウム ブロマイド、セチルピリジニウムクロライド及び他の塩;C8−32脂肪酸及び その塩;コール酸及びその誘導体例えばデオキシコレート、及びその塩、ウルソ デオキシコール酸、及びタウロコール酸;酒石酸のC8−56ジエステル類;ホ スファチジル酸及びホスファチジルセリン等の燐脂質類;乳酸のC5−29モノ エステル類;アルキル、オレフィン及びアルキルアリール誘導体を含めたC8− 20スルホネート類;トリデシル及びドデシルベンゼンスルホン酸類;及びC5 −33サルコシン及びべタイン誘導体類;ホスファチジルエタノールアミン、ス フィゴミエリン類、エトキシル化ひまし油;C5−29モノグリセリド類及びそ のエトキシル化誘導体類;C15−60ジグリセリド類及び1〜90のPOE基 を有しているそのポリオキシエチレン誘導体類;長鎖脂肪酸のC10−40エス テル類;C10−40アルコール類;C8−96エトキシル化脂肪酸エステル類 ;C14−130庶糖脂肪酸エステル類;及びC20−130ソルビトール及び ソルビタンモノエステル、ジエステル及びトリエステル類及び0〜90のPOE 基を有しているそのポリオキシエチレン(POE)誘導体類からなる群から選ば れる請求項52に記載の組成物。 54.水性粒体を添加することによって油中水滴型ミクロエマルジョンを水中油 滴型エマルジョンに転換することをさらに含む請求項53に記載の方法。 55.転換段階が投与段階以前である請求項54に記載の方法。 56.油中水滴型ミクロエマルジョンが水中油滴型ミクロエマルジョンに転換す る請求項54に記載の方法。 57.水相が転換段階前に油中水滴型ミクロエマルジョンの約0.1〜約20容 量%である請求項54に記載の方法。 58.表面活性剤の混合物が約5未満のHLB値を有する表面活性剤と少なくと も9のHLB値を有する表面活性剤を含む請求項54に記載の方法。 59.表面活性剤が(i)C9−C13モノグリセリド類、モノ及びポリ不飽和 脂肪酸のC19−C25モノグリセリド類、C15−C23のジグリセリド類、 モノ及びポリ不飽和脂肪酸のC35−C47ジグリセリド類からなる群から選ば れる少なくとも1種の表面活性剤、及び(ii)C20−C130ソルビトール 及びソルビタンモノエステル、ジエステル及びトリエステル及び0〜90のオキ シエチレン基を有するそのポリオキシエチレン誘導体からなる群から選ばれる少 なくとも1種の表面活性剤を含有している混合物である請求項57に記載の方法 。 60.油中水滴型ミクロエマルジョンが室温で固体である請求項54に記載の方 法。 61.7〜31個の炭素原子を有するブロピレングリコールのジエステル及び9 〜45個の炭素原子を有するトリグリセリドからなる群から選ばれる油から本質 的に油相がなっている請求項54に記載の方法。 62.活性物質がカルシトニン、インシュリン、フィブリノゲン拮抗剤、成長ホ ルモン放出ペプチド、インターロイキン類、エリトロポエチン類、コロニー刺激 因子類、RGDペプチド類、ヘマト調節ペプチド類(hematoregula torypeptides)、バソブレッシン、コラーゲナーゼ阻害剤類、アン ギオテンシン阻害剤類、哺乳類成長ホルモン類、エリトロポエチン類、ヘバリン 類、インターロイキン類、凝固因子類、コロニー刺激因子類、視床下部性放出ペ プチド類、組織プラスミノーゲン活性化因子、アトリアルナトリウム利尿性ペプ チド類(atrialnatriureticpeptides)、腫瘍壊死因 子からなる群から選択される請求項51、54又は56に記載の方法。 63.活性物質がカルシトニン、インシュリン又は人成長ホルモンである請求項 62に記載の方法。 64.活性物質がフィブリノゲン拮抗剤である請求項51、54又は56に記載 の方法。 65.活性物質が配列シクロ(S,S)一Nα−アセチル−Cys−(Nα−メ チル)Arg−Gly−Asp−Pen−NH2を有するペプチドである請求項 64に記載の方法。 66.活性物質が成長ホルモン放出ペプチドである請求項51、54又は56に 記載の方法。 67.活性物質が配列【配列があります】を有するペプチドである請求項66に 記載の方法。 68.グリセロールとラウリン酸のトリエステル対ジエステルの混合物を含有し ている約5〜80%(v/v)の組成物、 ポリオキシエチレンソルビタモノレ エート約15〜50%(v/v)、 カブリン酸とカブリル酸のモノ及びジグリセリドの混合物約3〜11%(v/v )、 長鎖モノグリセリド類の約2〜6%(v/v)、生物活性剤を含有している水性 25%(w/w)ソルビトールと25%(w/w)ブロピレングリコール溶液の 約6〜42%(v/v)を含んでいる生物活性治療用物質の分配の為の油中水、 滴型ミクロエマルジョン。 69.活性物質がカルシトニン、インシュリン、フィブリノゲン拮抗剤、成長ホ ルモン放出ペプチド、インターロイキン類、エリトロポエチン類、コロニー刺激 因子類、RGDペプチド類、ヘマト調節ペプチド類、バソブレッシン、コラーゲ ナーゼ阻害剤類、アンギオテンシン阻害剤類、哺乳類成長ホルモン類、エリトロ ポエチン類、ヘバリン類、インターロイキン類、凝固因子類、コロニー刺激因子 類、視床下部性放出ペプチド類、組織プラスミノーゲン活性化因子、アトリアル ナトリウム利尿性ペプチド類、腫瘍壊死因子からなる群から選択される請求項6 8に記載の組成物。 70.活性物質がカルシトニン、インシュリン又は人成長ホルモンである請求項 69に記載の組成物。 71.活性物質がフィブリノゲン拮抗剤である請求項68に記載の組成物。 72.活性物質が配列シクロ(S,S)−Nα−アセチル−Cys−(Nα−メ チル)Arg−Gly−Asp−Pen−NH2のを有するペプチドである請求 項71に記載の方法。 73.活性物質が成長ホルモン放出ペプチドである請求項68に記載の方法。 74.活性物質が配列【配列があります】を有するペプチドである請求項73に 記載の方法。 75.油、相、水相及び表面活性剤混合物の相対割合が図1の面積A内に記載さ れた通りであり、水相が活性物質を含んでいる、生物活性の治療用物質の分配の 為の油中水滴型ミクロエマルジョン。 76.活性物質がカルシトニン、インシュリン、フィブリノゲン拮抗剤、成長ホ ルモン放出ペプチド、インターロイキン類、エリトロポエチン類、コロニー刺激 因子類、RGDペプチド類、ヘマト調節ペプチド類、バソプレッシン、コラーゲ ナーゼ阻害剤類、アンギオテンシン阻害剤類、哺乳類成長ホルモン類、エリトロ ポエチン類、ヘバリン類、インターロイキン類、凝固因子類、コロニー刺激因子 類、視床下部性放出ペプチド類、組織プラスミノーゲン活性化因子、アトリアル ナトリウム利尿性ペプチド類、腫瘍壊死因子からなる群から選択される請求項7 5に記載のミクロエマルジョン。 77.活性物質がシクロ(S,S)−Nα−アセチル−Cys−(Nα−メチル )Arg−Gly−Asp−Pen−NH2及び【配列があります】からなる群 から選ばれるペプチドである請求項76に記載のミクロエマルジョン。 78.油相、水層及び表面活性剤混合物の相対割合が図3の面積内に記載された 通りであり、水相が活性物質を含んでいる、生物活性治療用物質の分配の為の油 中水滴型ミクロエマルジョン。 79.活性物質がカルシトニン、インシュリン、フィブリノゲン拮抗剤、成長ホ ルモン放出ペプチド、インターロイキン類、エリトロポエチン類、コロニー刺激 因子類、RGDペプチド類、ヘマト調節ペプチド類、バソブレッシン、コラーゲ ナーゼ阻害剤類、アンギオテンシン阻害剤類、哺乳類成長ホルモン類、エリトロ ポエチン類、ヘバリン類、インターロイキン類、凝固因子類、コロニー刺激因子 類、視床下部性放出ペプチド類、組織プラスミノーゲン活性化因子、アトリアル ナトリウム利尿性ペプチド類、腫瘍壊死因子からなる群から選択される請求項7 8に記載のミクロエマルジョン。 80.活性物質がシクロ(S,S)−Nα−アセチル−Cys−(Nα−メチル )Arg−Gly−Asp−Pen−NH2及び【配列があります】からなる群 から選ばれるブチドである請求項79に記載のミクロエマルジョン。 81.カブリン酸とカブリル酸のブロピレングリコールエステル約76重量%、 活性物質を含んでいる食塩水溶液約5重量%及びレシチン約1.6重量%及びポ リオキシエチレングリセロールトリリシノレート17重量%を含んでいる、生物 活性治療用物質の分配の為の油中水滴型ミクロエマルジョン。 82.活性物質がカルシトニン、インシュリン、フィブリノゲン拮抗剤、成長ホ ルモン放出ペプチド、インターロイキン類、エリトロポエチン類、コロニー刺激 因子類、RGDペプチド類、ヘマト調節ペプチド類、バソプレッシン、コラーゲ ナーゼ阻害剤類、アンギオテンシン阻害剤類、哺乳類成長ホルモン類、エリトロ ポエチン類、ヘバリン類、インターロイキン類、凝固因子類、コロニー刺激因子 類、視床下部性放出ペプチド類、組織プラスミノーゲン活性化因子、アトリアル ナトリウム利尿性ペプチド類、腫瘍壊死因子からなる群から選択される請求項8 1に記載のミクロエマルジョン。 83.活性物質がシクロ(S,S)−Nα−アセチル−Cys−(Nα−メチル )Arg−Gly−Asp−Pen−NH2及び【配列があります】からなる群 から選ばれるペプチドである請求項82に記載のミクロエマルジョン。 84.(a)(1)ミクロエマルジョンの全容量に基づいて約60容量%迄の、 生物活性の治療用水溶性物質の有効量を含む内部的に分散された水相、 (2)少なくとも1種の製薬上受け入れられる油を含む連続油相、及び (3)約7〜14のHLB値を有している表面活性剤又は表面活性剤混合物、を 含む油中水滴型ミクロエマルジョンを準備し、そして、 (b)約室温又はそれ以上に於て、少なくとも1時間該油中水滴型ミクロエマル ジョンを貯蔵することからなり、ここで活性物質の水対油分配係数が10:1よ りも大きく、そして、 該ミクロエマルジョンの該水相の活性が該水相単独中に貯蔵された該活性物質の 活性よりも大きいが、その他の点では同じ状態であることを特徴としている生物 活性治療用物質を貯蔵する方法。 85.活性物質が蛋白質、ペプチド、免疫原又は製薬上活性物質である請求項1 に記載の方法。 86.(a)(1)表皮の孔の平均粒径よりも大きな平均粒径を有している生物 活性治療用水溶性物質の有効量を含む、内部的に分散された水相、 (2)少なくとも1種の製薬上受け入れられる油を含んでいる連続油相、及び (3)少なくとも約7のHLBを有している表面活性剤又は表面活性剤混合物、 を含む油中水滴型ミクロエマルジョンを傷に適用することからなり、ここで油中 水滴型ミクロエマルジョンの合計容量に基づく水相の容量%が約60%まててあ ることを特徴とする、表皮が部分的に除去された皮膚の傷を処置する方法。 87.活性物質が少なくとも5000の平均分子量を有しており、活性物質が蛋 白質分解酵素及び成長因子からなる群から選択され、そして該方法が水性粒体の 添加により油中水滴型ミクロエマルジョンを水中油滴型エマルジョンに転換する ことを含んでいる請求項86に記載の方法。 88.(a)表皮の孔の平均粒径よりも大きな平均粒径を有している蛋白質分解 酵素及び成長因子からなる群から選ばれる生物活性治療用水溶性物質の有効量を 含む、内部的に分散された水相、 (b)少なくとも1種の製薬上受け入れられる油を含んでいる連続油相、及び (c)少なくとも約7のHLBを有している表面活性剤又は表面活性剤混合物を 含み、そして油中水滴型ミクロエマルジョンの合計容量に基づく水の容量%が約 60%までであり、 活性物質に対する水対油分配係数が10:1よりも大きい、皮膚の処置のための 油中水滴型ミクロエマルジョン。 89.活性物質が少なくとも約5000の平均分子量を有し、活性物質の粒寸法 が約3〜約100nmである請求項88に記載のミクロエマルジョン。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68769191A | 1991-04-19 | 1991-04-19 | |
US687,691 | 1991-04-19 | ||
US83734792A | 1992-02-14 | 1992-02-14 | |
US837,347 | 1992-02-14 | ||
US84193192A | 1992-02-25 | 1992-02-25 | |
US841,931 | 1992-02-25 | ||
PCT/US1992/003086 WO1992018147A1 (en) | 1991-04-19 | 1992-04-15 | Convertible microemulsion formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH06507172A true JPH06507172A (ja) | 1994-08-11 |
Family
ID=27418494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4511743A Ceased JPH06507172A (ja) | 1991-04-19 | 1992-04-15 | 転換可能なミクロエマルジョン処方剤 |
Country Status (16)
Country | Link |
---|---|
US (3) | US5444041A (ja) |
EP (1) | EP0580778B1 (ja) |
JP (1) | JPH06507172A (ja) |
CN (1) | CN1066183A (ja) |
AT (1) | ATE183099T1 (ja) |
AU (1) | AU668509B2 (ja) |
CA (1) | CA2108266C (ja) |
DE (1) | DE69229779T2 (ja) |
DK (1) | DK0580778T3 (ja) |
ES (1) | ES2136620T3 (ja) |
GR (1) | GR3031718T3 (ja) |
IE (1) | IE921212A1 (ja) |
IL (1) | IL101613A (ja) |
MX (1) | MX9201816A (ja) |
PT (1) | PT100400B (ja) |
WO (1) | WO1992018147A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029773A1 (fr) * | 1996-02-13 | 1997-08-21 | The Nisshin Oil Mills, Ltd. | Emulsion et poudre renfermant un vaccin et destinees a une administration orale, et procede de production associe |
JP2005515197A (ja) * | 2001-12-03 | 2005-05-26 | ドー バイオファーマ インコーポレイテッド | 安定化された逆ミセル組成物およびその使用 |
JP2007509956A (ja) * | 2003-10-27 | 2007-04-19 | ダウ・コーニング・コーポレイション | 局所適用のための調製物及び活性剤の基体への送達方法 |
WO2009041105A1 (ja) * | 2007-09-27 | 2009-04-02 | Riken Vitamin Co., Ltd. | ソフトカプセル充填用液状組成物 |
JP2009242334A (ja) * | 2008-03-31 | 2009-10-22 | Riken Vitamin Co Ltd | ソフトカプセル充填用液状組成物 |
JP2010195788A (ja) * | 2001-06-05 | 2010-09-09 | Regents Of The Univ Of Michigan | ナノエマルジョンワクチン |
JP2017081896A (ja) * | 2015-10-23 | 2017-05-18 | エルジー バイオナノ, エルエルシーLG Bionano, LLC | 可逆的な連続相及び分散相を有するナノエマルション |
Families Citing this family (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2136620T3 (es) * | 1991-04-19 | 1999-12-01 | Lds Technologies Inc | Formulaciones de microemulsiones convertibles. |
US5688761A (en) * | 1991-04-19 | 1997-11-18 | Lds Technologies, Inc. | Convertible microemulsion formulations |
WO1994008610A1 (en) * | 1992-10-16 | 1994-04-28 | Smithkline Beecham Corporation | Pharmaceutical emulsion compositions |
EP0671929A4 (en) * | 1992-10-16 | 1996-09-25 | Smithkline Beecham Corp | COMPOSITIONS. |
CA2147272C (en) * | 1992-10-16 | 1999-12-21 | Albert J. Owen | Convertible microemulsion formulations |
EP0666752A4 (en) * | 1992-10-16 | 1996-09-11 | Smithkline Beecham Corp | THERAPEUTIC MICROEMULSIONS. |
DK17093D0 (da) * | 1993-02-15 | 1993-02-15 | Lyfjathroun H F | Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder |
JPH06279228A (ja) * | 1993-03-30 | 1994-10-04 | Kao Corp | 発泡性組成物 |
DE69431310T2 (de) * | 1993-04-19 | 2003-05-22 | Inst Advanced Skin Res Inc | Mikroemulsionszubereitung enthaltend eine schwer absorbierbare substanz |
US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
JPH09512037A (ja) * | 1993-09-29 | 1997-12-02 | コンソルツイオ・テクノバイオチツプ・ソチエタ・コンソルテイレ・エイ・アール・エル | タンパク質薄フィルム及びその製造で用いるための組成物 |
DE4335045A1 (de) * | 1993-10-14 | 1995-04-20 | Henkel Kgaa | Fließfähiges Emulsionskonzentrat |
CA2176927C (en) * | 1993-11-17 | 2010-03-23 | Seang H. Yiv | Transparent liquid for encapsulated drug delivery |
CA2185803C (en) * | 1994-03-18 | 2006-07-11 | Edward M. Rudnic | Emulsified drug delivery systems |
US5672358A (en) * | 1994-06-21 | 1997-09-30 | Ascent Pharmaceuticals, Inc. | Controlled release aqueous emulsion |
GB9412394D0 (en) * | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
JPH0827018A (ja) * | 1994-07-22 | 1996-01-30 | Sanwa Kagaku Kenkyusho Co Ltd | 生理活性ペプチド又は蛋白質を含有する薬剤組成物 |
US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
AU698317B2 (en) | 1995-02-25 | 1998-10-29 | Cancer Research Technology Limited | Transgenic animals as model of psoriasis |
DE19509079A1 (de) * | 1995-03-15 | 1996-09-19 | Beiersdorf Ag | Kosmetische oder dermatologische Mikroemulsionen |
US6689370B1 (en) | 1995-04-20 | 2004-02-10 | Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
FR2733151B1 (fr) * | 1995-04-20 | 1997-05-23 | Seppic Sa | Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines |
US6117432A (en) * | 1995-04-20 | 2000-09-12 | Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
US6008228A (en) * | 1995-06-06 | 1999-12-28 | Hoffman-La Roche Inc. | Pharmaceutical compositions containing proteinase inhibitors |
US5766636A (en) * | 1995-09-06 | 1998-06-16 | Natura, Inc. | Edible, low calorie compositions of a carrier and an active ingredient and methods for preparation thereof |
SE9503143D0 (sv) | 1995-09-12 | 1995-09-12 | Astra Ab | New preparation |
ATE353225T1 (de) * | 1995-11-30 | 2007-02-15 | Chemo Sero Therapeut Res Inst | Öladjuvierter impfstoff und verfahren zu seiner herstellung |
US5858401A (en) * | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US6245349B1 (en) | 1996-02-23 | 2001-06-12 | éLAN CORPORATION PLC | Drug delivery compositions suitable for intravenous injection |
WO1997035560A1 (en) | 1996-03-28 | 1997-10-02 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved echogenic liposome compositions |
US5726154A (en) * | 1996-06-28 | 1998-03-10 | University Of Utah Research Foundation | Stabilization and oral delivery of calcitonin |
DE69723375T3 (de) * | 1996-08-30 | 2012-12-20 | Ajinomoto Co., Inc. | Waschmittelzusammensetzung |
AU4491697A (en) * | 1996-09-27 | 1998-04-17 | Trega Biosciences, Inc. | Compositions of therapeutic agents suitable for oral administration |
SE511313C2 (sv) | 1997-01-13 | 1999-09-06 | Gs Dev Ab | Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US7585645B2 (en) * | 1997-05-27 | 2009-09-08 | Sembiosys Genetics Inc. | Thioredoxin and thioredoxin reductase containing oil body based products |
IS4518A (is) * | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
US6217886B1 (en) | 1997-07-14 | 2001-04-17 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved micelle compositions |
FR2767064B1 (fr) * | 1997-08-07 | 1999-11-12 | Centre Nat Rech Scient | Procede de liberation d'un principe actif contenu dans une emulsion multiple |
US7153845B2 (en) * | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US8765177B2 (en) * | 1997-09-12 | 2014-07-01 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6024786A (en) * | 1997-10-30 | 2000-02-15 | Hewlett-Packard Company | Stable compositions of nano-particulate unmodified pigments and insoluble colorants in aqueous microemulsions, and principle of stability and methods of formation thereof |
US20020031513A1 (en) * | 1997-11-24 | 2002-03-14 | Shamir Leibovitz | Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals |
US7070799B1 (en) * | 1998-02-10 | 2006-07-04 | Generex Pharmaceuticals, Inc. | Method for administering insulin to the buccal region |
US6017545A (en) * | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
US6221378B1 (en) | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
DE19806889A1 (de) * | 1998-02-19 | 1999-08-26 | Beiersdorf Ag | Verwendung von Acyl-Carnitin |
US20030180368A1 (en) * | 1998-03-14 | 2003-09-25 | Cenes Drug Delivery Limited | Production of microparticles |
TWI241915B (en) | 1998-05-11 | 2005-10-21 | Ciba Sc Holding Ag | A method of preparing a pharmaceutical end formulation using a nanodispersion |
US6241969B1 (en) | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
US8466134B1 (en) | 1998-06-26 | 2013-06-18 | Athena Neurosciences, Inc. | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
FR2780644B1 (fr) * | 1998-07-03 | 2001-07-20 | Oreal | Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse et d'une phase aqueuse, stabilisee a l'aide de particules de gel cubique |
EP0976394A1 (en) * | 1998-07-30 | 2000-02-02 | Biosearch Italia S.p.A. | New injectable formulations |
EP1104290B1 (en) | 1998-08-13 | 2010-03-31 | Cima Labs Inc. | Microemulsions as solid dosage forms for oral administration |
US6174547B1 (en) * | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
DE19859427A1 (de) * | 1998-12-22 | 2000-06-29 | Beiersdorf Ag | Kosmetische oder pharmazeutische lecithinhaltige Gele oder niedrigviskose, lecithinhaltige O/W-Mikroemulsionen |
GB9903547D0 (en) | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US6458383B2 (en) | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
EP1064934A1 (en) * | 1999-06-30 | 2001-01-03 | Applied Research Systems ARS Holding N.V. | GRF-containing lyophilized pharmaceutical composition |
US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
GB0005736D0 (en) * | 2000-03-09 | 2000-05-03 | G C Hahn Co Ltd | Low fat edible emulsions |
DE10015463B4 (de) * | 2000-03-29 | 2008-01-10 | Heide, Peter Edgar, Dr. | Creme in Form einer überwässerten Wasser-in-Öl-Emulsion |
WO2001097837A1 (en) * | 2000-06-21 | 2001-12-27 | Ferring Bv | Solubilised protein vaccines |
US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
EP1383540B1 (en) | 2000-07-31 | 2009-04-29 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
US20100129332A1 (en) * | 2000-07-31 | 2010-05-27 | Tamar Tennenbaum | Methods and pharmaceutical compositions for healing wounds |
US20030148924A1 (en) * | 2002-07-09 | 2003-08-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions of healing wounds |
US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
US6582682B2 (en) * | 2000-10-30 | 2003-06-24 | Noville, Inc. | Oral care compositions comprising stabilized chlorine dioxide |
EP1346726A4 (en) * | 2000-12-25 | 2004-09-15 | Shiseido Co Ltd | FRAGRANCE COMPOSITION STIMULATING THE SYMPATHETIC SYSTEM |
US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6867183B2 (en) | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US6692771B2 (en) * | 2001-02-23 | 2004-02-17 | Cima Labs Inc. | Emulsions as solid dosage forms for oral administration |
US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7196059B2 (en) | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US6913903B2 (en) | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
WO2003047494A2 (en) * | 2001-12-03 | 2003-06-12 | Dor Biopharma Inc. | Reverse micelle compositions and uses thereof |
KR20040095232A (ko) * | 2002-02-25 | 2004-11-12 | 라이프자트로운 에이치에프 | 흡수촉진제 |
US20050124705A1 (en) * | 2002-03-28 | 2005-06-09 | Beiersdorf Ag | Cosmetic or pharmaceutical, low-viscosity oil-in-water emulsions containing phospholipids |
EP1506035A1 (en) * | 2002-05-06 | 2005-02-16 | Vectura Limited | Application device for topical administration of pharmaceutical agents |
AU2003236521A1 (en) * | 2002-06-13 | 2003-12-31 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
DE10226990A1 (de) * | 2002-06-18 | 2004-03-18 | Sanguibiotech Ag | Topisch applizierbare Mikro-Emulsionen mit binärer Phasen- und Wirkstoffdifferenzierbarkeit, deren Herstellung und deren Verwendung, insbesondere zur Versorgung der Haut mit bioverfügbarem Sauerstoff |
CA2430889A1 (en) * | 2002-06-19 | 2003-12-19 | Bayer Corporation | Stabilization of brain natriuretic peptide (bnp) in blood samples, methods and compositions related thereto |
US6855332B2 (en) | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
US20040115226A1 (en) * | 2002-12-12 | 2004-06-17 | Wenji Li | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same |
US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
KR100515752B1 (ko) * | 2003-05-16 | 2005-09-20 | 주식회사 엘지화학 | 초임계 유체를 이용한 스티렌과 말레이미드 공중합체의제조 방법 |
US7445933B2 (en) * | 2003-07-16 | 2008-11-04 | Abbott Laboratories, Inc. | Stable calibrators or controls for measuring human natriuretic peptides |
US7291501B2 (en) * | 2003-07-16 | 2007-11-06 | Abbott Laboratories | Stable compositions for measuring human natriuretic peptides |
US7004340B2 (en) * | 2003-07-25 | 2006-02-28 | Alpha Security Products, Inc. | Bottle security device |
CA2535029C (en) | 2003-08-07 | 2013-07-16 | Healor Ltd. | Pharmaceutical compositions and methods for accelerating wound healing |
US9259390B2 (en) * | 2003-08-13 | 2016-02-16 | The University Of Houston System | Parenteral and oral formulations of benzimidazoles |
CA2537029C (en) * | 2003-11-26 | 2013-03-12 | Likan Liang | Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
PE20050596A1 (es) * | 2003-12-19 | 2005-10-18 | Novartis Ag | Microemulsion que comprende un inhibidor renina |
US20050232974A1 (en) * | 2004-04-19 | 2005-10-20 | Gore Makarand P | System and a method for pharmaceutical dosage preparation using jettable microemulsions |
US20050238675A1 (en) * | 2004-04-26 | 2005-10-27 | Wenjie Li | Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications |
US7357957B2 (en) * | 2004-05-07 | 2008-04-15 | Fractec Research & Development Inc. | Spreadable food product |
US20070093610A1 (en) * | 2004-05-12 | 2007-04-26 | Kim Dong R | Method for preparing styrene and maleimide copolymer using super critical fluid |
WO2006014673A2 (en) | 2004-07-19 | 2006-02-09 | Nobex Corporation | Insulin-oligomer conjugates, formulations and uses thereof |
EP1781257B1 (en) * | 2004-08-13 | 2018-12-19 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
AU2005283726A1 (en) * | 2004-09-13 | 2006-03-23 | Bharat Serums & Vaccines Ltd. | Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy |
DE102004049574A1 (de) | 2004-10-12 | 2006-04-20 | Doris Dr. Barnikol-Keuten | Arzneimittel und System zur perkutanen Arzneistoffverabreichung |
ES2507097T3 (es) * | 2005-01-19 | 2014-10-14 | Sumitomo Dainippon Pharma Co., Ltd. | Composición emulsionada para dilución y composición de vacuna contra el cáncer |
US20060205904A1 (en) * | 2005-03-11 | 2006-09-14 | St Clair David J | Oil gels of controlled distribution block copolymers and ester oils |
BRPI0607549A2 (pt) | 2005-04-15 | 2009-09-15 | Clarus Therapeutics Inc | sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos |
US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
CA2616166A1 (en) * | 2005-07-22 | 2007-02-01 | The Regents Of The University Of California | Heparin compositions and selectin inhibition |
US20070042007A1 (en) * | 2005-08-19 | 2007-02-22 | Joseph Schwarz | Topical composition for delivery of salicylate esters |
ZA200802546B (en) * | 2005-08-29 | 2009-10-28 | Healor Ltd | Methods and compositions for prvention and treatment of diabetic and aged skin |
DOP2006000267A (es) * | 2005-11-30 | 2009-06-30 | Colgate Palmalive Company | Composiciones y métodos de limpieza |
WO2007070983A1 (en) * | 2005-12-22 | 2007-06-28 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
JP5450052B2 (ja) * | 2006-04-07 | 2014-03-26 | メリオン リサーチ Iii リミテッド | 強化剤を含む固体経口投与剤形 |
GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
US9918934B2 (en) * | 2006-12-12 | 2018-03-20 | Edgar Joel Acosta-Zara | Linker-based lecithin microemulsion delivery vehicles |
US7968635B2 (en) * | 2006-12-28 | 2011-06-28 | Continental Ag | Tire compositions and components containing free-flowing filler compositions |
FR2915101B1 (fr) * | 2007-04-23 | 2011-07-29 | Fabre Pierre Dermo Cosmetique | Composition dermatologique pour la prevention et/ou le traitement de la rosacee, de la couperose ou des peaux qui presentent des rougeurs diffuses ou des petits vaisseaux dilates |
AU2008281374B2 (en) * | 2007-07-30 | 2012-05-31 | Healor Ltd. | Pharmaceutical composition for treating wounds and related methods |
ES2664822T3 (es) | 2007-10-16 | 2018-04-23 | Biocon Limited | Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma |
JP2011508770A (ja) * | 2008-01-02 | 2011-03-17 | クリングルファーマ株式会社 | タンパク質及びペプチドの制御的投与のための局所投与用組成物 |
EP2288369B1 (en) * | 2008-05-07 | 2014-07-09 | Merrion Research III Limited | Compositions of gnrh related compounds and processes of preparation |
US20100004196A1 (en) * | 2008-06-17 | 2010-01-07 | Hopitaux Universitaires De Geneve | Heparan sulfate proteoglycan composition and use thereof |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
MX2011007970A (es) * | 2009-02-24 | 2011-10-19 | Healor Ltd | Agentes terapeuticos de visfatina para el tratamiento de acne y otras condiciones. |
WO2010099255A1 (en) * | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
CA2773486C (en) * | 2009-09-10 | 2017-10-10 | Merial Limited | New vaccine formulations comprising saponin-containing adjuvants |
WO2011069629A2 (en) * | 2009-12-10 | 2011-06-16 | Merck Patent Gmbh | Pharmaceutical composition comprising oligopeptides |
WO2011083483A2 (en) | 2010-01-11 | 2011-07-14 | Healor Ltd. | Method for treatment of inflammatory disease and disorder |
CN102753150A (zh) | 2010-01-12 | 2012-10-24 | 诺沃—诺迪斯克有限公司 | 用于口服给予胰岛素肽的药物组合物 |
US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
WO2011120033A1 (en) * | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
FR2964332A1 (fr) * | 2010-09-06 | 2012-03-09 | Capsum | Nanodispersions inverses stables |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9168309B2 (en) | 2010-12-01 | 2015-10-27 | Omnis Biotechnology Inc. | Thixotropic compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
EP2661273A4 (en) | 2011-01-07 | 2014-06-04 | Merrion Res Iii Ltd | IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION |
GB201107630D0 (en) * | 2011-05-06 | 2011-06-22 | Proxima Concepts Ltd | Microemulsions |
PE20191242A1 (es) | 2011-10-25 | 2019-09-16 | Prothena Biosciences Ltd | Formulaciones de anticuerpo y metodos |
MX2016013201A (es) * | 2014-04-09 | 2017-04-25 | Nanoceutica Laboratories Pvt Ltd | Composicion y metodo para producir una nanoformulacion de bioactivos insolubles en agua en una base acuosa. |
EP2946788A1 (en) | 2014-05-23 | 2015-11-25 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
WO2016120378A1 (en) | 2015-01-29 | 2016-08-04 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
KR20190052072A (ko) * | 2016-09-16 | 2019-05-15 | 케민 인더스트리즈, 인코포레이티드 | 동물 사료 보충물 |
US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
KR101786914B1 (ko) * | 2017-01-31 | 2017-11-15 | 주식회사 삼양사 | 피부 리프팅 또는 탄력 개선을 위한 점착성 탄력 밴드 |
CN112915916B (zh) * | 2021-01-29 | 2022-05-24 | 江南大学 | 一种pH刺激响应型胆汁盐Pickering复合乳化剂 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US962957A (en) * | 1909-03-26 | 1910-06-28 | Albert G Hermanson | Mole-plow. |
US962956A (en) * | 1909-10-02 | 1910-06-28 | Almon E Hall | Coin-mailing device. |
US3083142A (en) * | 1958-02-27 | 1963-03-26 | Glaxo Group Ltd | Improved swine erysipelas vaccine |
US3100178A (en) * | 1961-08-31 | 1963-08-06 | Parke Davis & Co | Vaccine products and method of preparing same |
US3149036A (en) * | 1961-10-16 | 1964-09-15 | Merck & Co Inc | Adjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agent |
US3438782A (en) * | 1965-01-18 | 1969-04-15 | Vitamins Inc | Edible oil supplement for feed ration |
US3492399A (en) * | 1965-09-27 | 1970-01-27 | Samuel J Prigal | Emulsion compositions and methods |
GB1171125A (en) * | 1966-06-08 | 1969-11-19 | Glaxo Lab Ltd | Improvements in or relating to Injectable Preparations |
US3776857A (en) * | 1971-09-24 | 1973-12-04 | Witco Chemical Corp | Water-in-oil emulsions |
US3983228A (en) * | 1973-08-28 | 1976-09-28 | Merck & Co., Inc. | Water-in-oil adjuvant composition |
DE2514873C2 (de) * | 1975-04-05 | 1983-12-29 | Merck Patent Gmbh, 6100 Darmstadt | Salbengrundlage |
FR2321896A1 (fr) * | 1975-08-29 | 1977-03-25 | Anvar | Agents adjuvants immunologiques actifs en solution aqueuse |
US4122158A (en) * | 1976-09-23 | 1978-10-24 | Alza Corporation | Topical therapeutic preparations |
JPS5940137B2 (ja) * | 1976-10-14 | 1984-09-28 | 武田薬品工業株式会社 | 経口投与用医薬組成物 |
US4104403A (en) * | 1976-12-21 | 1978-08-01 | Witco Chemical Corporation | Water-oil emulsions and method of preparing same |
US4183918A (en) * | 1977-03-08 | 1980-01-15 | Exxon Research & Engineering Co. | Detoxifying-medicinal emulsions |
US4241051A (en) * | 1977-11-04 | 1980-12-23 | Christie Robert B | Calcitonin |
US4395394A (en) * | 1979-10-26 | 1983-07-26 | Pfizer Inc. | Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants |
IT1139177B (it) * | 1980-09-19 | 1986-09-24 | Elf Aquitaine | Microemulsione di sostanze nutritive |
FR2502951B1 (fr) * | 1981-04-06 | 1985-12-06 | Sandoz Sa | Compositions pharmaceutiques topiques sous forme d'une micro-emulsion |
EP0073856A1 (en) * | 1981-08-28 | 1983-03-16 | Gist-Brocades N.V. | Infectious-bronchitis vaccines for poultry, combined infectious-bronchitis vaccines, process for preparing such vaccines, process for preventing infectious bronchitis and infectious-bronchitis virus strain |
NL8301996A (nl) * | 1983-06-06 | 1985-01-02 | Duphar Int Res | Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins. |
US4731384A (en) * | 1983-07-01 | 1988-03-15 | Troponwerke Gmbh & Co, Kg | Etofenamate formulation |
JPS6061535A (ja) * | 1983-08-24 | 1985-04-09 | エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト | 製薬学的組成物 |
US4692433A (en) * | 1983-10-12 | 1987-09-08 | The Regents Of The University Of California | Method and composition for regulating serum calcium levels of mammals |
DE3339236A1 (de) * | 1983-10-28 | 1985-05-09 | Bayer Ag | Arzneimittelzubereitung |
DE3406497A1 (de) * | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
JPS60199833A (ja) * | 1984-03-26 | 1985-10-09 | Meiji Milk Prod Co Ltd | 医薬品、化粧品等用w/o/w型複合エマルジヨンの製造法 |
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4914084A (en) * | 1984-05-09 | 1990-04-03 | Synthetic Blood Corporation | Composition and method for introducing heme, hemoproteins, and/or heme-hemoprotein complexes into the body |
CH662944A5 (it) * | 1984-10-18 | 1987-11-13 | Pier Luigi Prof Dr Luisi | Procedimento per la preparazione di biocompatibili di micelle inverse di biocompatibili e loro utilizzazione. |
GB8426467D0 (en) * | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
JPS61185332A (ja) * | 1985-02-12 | 1986-08-19 | Morinaga Milk Ind Co Ltd | 安定な油中水型乳化物およびその製造法 |
US4690774A (en) * | 1985-09-11 | 1987-09-01 | Chesebrough Pond's Inc. | Novel translucent water in oil emulsions |
US4980084A (en) * | 1985-09-11 | 1990-12-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Water rinsable petroleum jelly compositions |
US5036045A (en) * | 1985-09-12 | 1991-07-30 | The University Of Virginia Alumni Patents Foundation | Method for increasing growth hormone secretion |
US4797272A (en) * | 1985-11-15 | 1989-01-10 | Eli Lilly And Company | Water-in-oil microemulsions for cosmetic uses |
US4781914A (en) * | 1985-12-04 | 1988-11-01 | Charles Of The Ritz Group Ltd. | Sunscreen and moisturizer |
US4803070A (en) * | 1986-04-15 | 1989-02-07 | Ribi Immunochem Research Inc. | Immunological emulsion adjuvants for polysaccharide vaccines |
US4806352A (en) * | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
US4806350A (en) * | 1986-04-18 | 1989-02-21 | Norden Laboratories, Inc. | Vaccine formulation |
JPS62270521A (ja) * | 1986-05-16 | 1987-11-24 | Green Cross Corp:The | フルルビプロフエン眼投与製剤 |
SE457693B (sv) * | 1986-07-01 | 1989-01-23 | Drilletten Ab | Komposition med reglerad frigoering vari ett biologiskt material aer loest eller dispergerat i en l2-fas |
US5371109A (en) * | 1986-07-01 | 1994-12-06 | Drilletten Ab | Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase |
EP0257368B1 (en) * | 1986-08-11 | 1992-03-25 | American Cyanamid Company | Compositions for parenteral administration and their use |
GB8630273D0 (en) * | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
IE60024B1 (en) * | 1987-02-03 | 1994-05-18 | Stiefel Laboratories Ltd | Microemulsions |
CA1301642C (en) * | 1987-03-30 | 1992-05-26 | Howard Bernard Dawson | Chemical formulations |
US4720353A (en) * | 1987-04-14 | 1988-01-19 | Richardson-Vicks Inc. | Stable pharmaceutical w/o emulsion composition |
US5064653A (en) * | 1988-03-29 | 1991-11-12 | Ferris Mfg. Co. | Hydrophilic foam compositions |
US5026825A (en) * | 1988-09-08 | 1991-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Intranasal calcitonin formulations |
KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
US5036108A (en) * | 1988-12-14 | 1991-07-30 | Kao Corporation | Water-in-oil emulsion cosmetic |
KR910004884B1 (ko) * | 1989-02-01 | 1991-07-15 | 한국식품개발연구원 | 유지류의 산화억제방법 |
US5002771A (en) * | 1989-02-06 | 1991-03-26 | Rorer Pharmaceutical Corp. | Calcitonin suppository formulations |
DE3919982A1 (de) * | 1989-06-19 | 1990-12-20 | Liedtke Pharmed Gmbh | Orale lipidarzneiform |
JP2785981B2 (ja) * | 1989-11-20 | 1998-08-13 | 株式会社資生堂 | 乳化組成物 |
US5045337A (en) * | 1990-04-19 | 1991-09-03 | The Procter & Gamble Company | Food microemulsion |
US5162378A (en) * | 1990-04-20 | 1992-11-10 | Revlon Consumer Products Corporation | Silicone containing water-in-oil microemulsions having increased salt content |
US5110606A (en) * | 1990-11-13 | 1992-05-05 | Affinity Biotech, Inc. | Non-aqueous microemulsions for drug delivery |
ES2136620T3 (es) * | 1991-04-19 | 1999-12-01 | Lds Technologies Inc | Formulaciones de microemulsiones convertibles. |
WO1993002664A1 (en) * | 1991-07-26 | 1993-02-18 | Smithkline Beecham Corporation | W/o microemulsions |
ZA925580B (en) * | 1991-07-26 | 1993-05-17 | Smithkline Beecham Corp | Pharmaceutical miroemulsions. |
WO1993006921A1 (en) * | 1991-10-04 | 1993-04-15 | Gs Biochem Ab | Particles, method of preparing said particles and uses thereof |
US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
WO1994008610A1 (en) * | 1992-10-16 | 1994-04-28 | Smithkline Beecham Corporation | Pharmaceutical emulsion compositions |
EP0671929A4 (en) * | 1992-10-16 | 1996-09-25 | Smithkline Beecham Corp | COMPOSITIONS. |
EP0666752A4 (en) * | 1992-10-16 | 1996-09-11 | Smithkline Beecham Corp | THERAPEUTIC MICROEMULSIONS. |
-
1992
- 1992-04-15 ES ES92911731T patent/ES2136620T3/es not_active Expired - Lifetime
- 1992-04-15 AU AU18966/92A patent/AU668509B2/en not_active Expired
- 1992-04-15 IE IE121292A patent/IE921212A1/en not_active IP Right Cessation
- 1992-04-15 CA CA002108266A patent/CA2108266C/en not_active Expired - Lifetime
- 1992-04-15 DK DK92911731T patent/DK0580778T3/da active
- 1992-04-15 WO PCT/US1992/003086 patent/WO1992018147A1/en active IP Right Grant
- 1992-04-15 DE DE69229779T patent/DE69229779T2/de not_active Expired - Lifetime
- 1992-04-15 JP JP4511743A patent/JPH06507172A/ja not_active Ceased
- 1992-04-15 EP EP92911731A patent/EP0580778B1/en not_active Expired - Lifetime
- 1992-04-15 AT AT92911731T patent/ATE183099T1/de active
- 1992-04-16 IL IL101613A patent/IL101613A/en not_active IP Right Cessation
- 1992-04-16 PT PT100400A patent/PT100400B/pt not_active IP Right Cessation
- 1992-04-18 CN CN92102762A patent/CN1066183A/zh active Pending
- 1992-04-20 MX MX9201816A patent/MX9201816A/es unknown
- 1992-05-20 US US07/885,202 patent/US5444041A/en not_active Expired - Lifetime
-
1995
- 1995-04-20 US US08/425,475 patent/US5646109A/en not_active Expired - Lifetime
- 1995-04-20 US US08/425,787 patent/US5633226A/en not_active Expired - Lifetime
-
1999
- 1999-11-03 GR GR990402810T patent/GR3031718T3/el unknown
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029773A1 (fr) * | 1996-02-13 | 1997-08-21 | The Nisshin Oil Mills, Ltd. | Emulsion et poudre renfermant un vaccin et destinees a une administration orale, et procede de production associe |
JP2010195788A (ja) * | 2001-06-05 | 2010-09-09 | Regents Of The Univ Of Michigan | ナノエマルジョンワクチン |
JP2013253086A (ja) * | 2001-06-05 | 2013-12-19 | Regents Of The Univ Of Michigan | ナノエマルジョンワクチン |
JP2005515197A (ja) * | 2001-12-03 | 2005-05-26 | ドー バイオファーマ インコーポレイテッド | 安定化された逆ミセル組成物およびその使用 |
JP2010280700A (ja) * | 2001-12-03 | 2010-12-16 | Soligenix Inc | 安定化された逆ミセル組成物およびその使用 |
JP2007509956A (ja) * | 2003-10-27 | 2007-04-19 | ダウ・コーニング・コーポレイション | 局所適用のための調製物及び活性剤の基体への送達方法 |
US7939570B2 (en) | 2003-10-27 | 2011-05-10 | Dow Corning Corporation | Controlled-release composition for topical application and a method of delivering an active agent to a substrate |
WO2009041105A1 (ja) * | 2007-09-27 | 2009-04-02 | Riken Vitamin Co., Ltd. | ソフトカプセル充填用液状組成物 |
JP2009242334A (ja) * | 2008-03-31 | 2009-10-22 | Riken Vitamin Co Ltd | ソフトカプセル充填用液状組成物 |
JP2017081896A (ja) * | 2015-10-23 | 2017-05-18 | エルジー バイオナノ, エルエルシーLG Bionano, LLC | 可逆的な連続相及び分散相を有するナノエマルション |
US9872832B2 (en) | 2015-10-23 | 2018-01-23 | LG Bionano, LLC | Nanoemulsions having reversible continuous and dispersed phases |
Also Published As
Publication number | Publication date |
---|---|
DK0580778T3 (da) | 2000-01-31 |
EP0580778A1 (en) | 1994-02-02 |
PT100400A (pt) | 1993-08-31 |
CN1066183A (zh) | 1992-11-18 |
DE69229779D1 (de) | 1999-09-16 |
US5633226A (en) | 1997-05-27 |
US5646109A (en) | 1997-07-08 |
IE921212A1 (en) | 1992-10-21 |
CA2108266A1 (en) | 1992-10-20 |
CA2108266C (en) | 2003-06-03 |
AU1896692A (en) | 1992-11-17 |
EP0580778B1 (en) | 1999-08-11 |
GR3031718T3 (en) | 2000-02-29 |
ATE183099T1 (de) | 1999-08-15 |
PT100400B (pt) | 1999-08-31 |
AU668509B2 (en) | 1996-05-09 |
WO1992018147A1 (en) | 1992-10-29 |
EP0580778A4 (en) | 1996-01-31 |
IL101613A (en) | 1998-02-22 |
US5444041A (en) | 1995-08-22 |
MX9201816A (es) | 1992-10-30 |
ES2136620T3 (es) | 1999-12-01 |
DE69229779T2 (de) | 1999-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06507172A (ja) | 転換可能なミクロエマルジョン処方剤 | |
US5688761A (en) | Convertible microemulsion formulations | |
EP0790822B1 (en) | Controlled release composition forming a reversed micellar (l2) structure or a normal micellar (l1) structure | |
Li et al. | Oral delivery of peptides and proteins using lipid-based drug delivery systems | |
US8546326B2 (en) | Glp-1 analogue formulations | |
JPH06509796A (ja) | W/oミクロエマルジョン | |
KR101494594B1 (ko) | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 | |
JPH05507685A (ja) | リン脂質で被覆した微細結晶である水不溶性薬剤の注射可能な製剤 | |
ITMI20001173A1 (it) | Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva. | |
AU667483B2 (en) | W/O microemulsions | |
JPH09510182A (ja) | カプセル封入されたドラッグデリバリー用透明液 | |
JPH08502492A (ja) | 治療用ミクロエマルジョン | |
JPH08505367A (ja) | 医薬用エマルジョン組成物 | |
US20230398132A1 (en) | PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME | |
EP0746331B1 (en) | Convertible microemulsion formulations | |
EP0684834A1 (en) | Microemulsions comprising therapeutic peptides | |
EP0684833A1 (en) | Microemulsions comprising therapeutic peptides | |
JPH08507065A (ja) | 医薬組成物含有のミクロエマルジョン | |
Souto et al. | Lipid Matrix Nanoparticles in Diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040525 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040820 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050607 |
|
RD12 | Notification of acceptance of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7432 Effective date: 20050616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050902 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051017 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060116 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060221 |